Coronary Syndrome
📧 Sign up to get email alerts when something new happens for Coronary Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-03-14FDA Approved: ENOXAPARIN SODIUM — Original Application (Amphastar Pharmaceuticals, Inc.)
FDA approved Amphastar Pharmaceuticals' generic enoxaparin sodium injection (ANDA 208600). This marks approval of a generic version of enoxa…
-
CLINICAL_TRIALS trial_result · 2019-03-01Clinical Trial Update: Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial [Phase 4]
Phase 4 trial evaluating responsiveness to platelet inhibition in patients on chronic antiplatelet therapy for acute coronary syndrome has c…
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: Routine Versus Selective Use of FFR to Guide PCI [Phase 4]
Phase 4 trial update comparing routine versus selective use of fractional flow reserve (FFR) to guide percutaneous coronary intervention (PC…
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Dose-escalation, Repeated and Single Oral Dosing Study [Phase 1]
Phase 1 dose-escalation study of an IlDong Pharmaceutical compound in acute coronary syndrome was terminated.
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Safety Study of APD-791 With Aspirin and/or Clopidogrel [Phase 1]
A Phase 1 safety study of APD-791 in combination with aspirin and/or clopidogrel for acute coronary syndrome has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-02-11Clinical Trial Update: CER-001 Atherosclerosis Regression ACS Trial [Phase 2]
Phase 2 trial CER-001 for atherosclerosis regression in acute coronary syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2019-02-08Clinical Trial Update: Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent [Phase 4]
This Phase 4 trial update indicates completion of a study evaluating short-term dual antiplatelet therapy in acute Coronary Syndrome patient…
-
CLINICAL_TRIALS research · 2019-02-05Clinical Trial Update: Oxidized LDL With Oxygen Therapy in Acute Coronary Syndrome.
An update on a clinical trial evaluating oxidized LDL with oxygen therapy in acute coronary syndrome. The current status of the trial is unk…
-
CLINICAL_TRIALS research · 2019-01-30Clinical Trial Update: Registry of Coronary Artery Ill Patients With Platelet Test Results
Registry trial currently recruiting to evaluate platelet test results in patients with Acute Coronary Syndrome and Myocardial Infarction und…
-
CLINICAL_TRIALS research · 2019-01-30Clinical Trial Update: Future Optimal Research and Care Evaluation
A clinical trial registration update for the Future Optimal Research and Care Evaluation study by J.M. ten Berg, investigating Acute Coronar…
-
CLINICAL_TRIALS trial_result · 2019-01-29Clinical Trial Update: Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With CPAP [NA]
A clinical trial evaluating attentional capacity and working memory in coronary artery disease patients with obstructive sleep apnea, and th…
-
CLINICAL_TRIALS guidance · 2019-01-25Clinical Trial Update: Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)
A completed clinical trial update discusses using platelet reactivity testing to guide adjustments in antiplatelet therapy after PCI, highli…
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: The FOVUS-ER Study: Focused Vascular Ultrasound to Risk Stratify Patients With Chest Pain in the ER [NA]
The update notes that the FOVUS-ER study evaluating focused vascular ultrasound to risk-stratify patients with chest pain in the emergency d…
-
FDA approval · 2019-01-23FDA Approved: TICAGRELOR — Original Application (Hisun Pharmaceuticals USA, Inc.)
The FDA approved an Original Application (ANDA) for ticagrelor from Hisun Pharmaceuticals USA, Inc., enabling a generic ticagrelor product t…
-
CLINICAL_TRIALS trial_result · 2019-01-15Clinical Trial Update: The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome [Phase 2, Phase 3]
Clinical trial evaluating melatonin for depression, anxiety, circadian and sleep disturbances in patients after acute coronary syndrome has …
-
FDA approval · 2018-12-21FDA Approved: BIVALIRUDIN — Supplemental Application (Civica, Inc.)
The FDA approved a supplemental application for BIVALIRUDIN from Civica, Inc., resulting in an approved update to the NDA.
-
FDA approval · 2018-12-20FDA Approved: HEPARIN SODIUM AND DEXTROSE — Supplemental Application (Hospira, Inc.)
FDA approved a supplemental application for Hospira's Heparin Sodium and Dextrose (heparin sodium) product, authorizing changes under the ND…
-
FDA approval · 2018-12-14FDA Approved: HEPARIN SODIUM — Original Application (NorthStar RxLLC)
The FDA approved NorthStar RxLLC's original application for generic heparin sodium (ANDA211005).
-
FDA approval · 2018-12-11FDA Approved: ENOXAPARIN SODIUM — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a Supplemental Application for enoxaparin sodium from Sanofi-Aventis U.S. LLC to update the product labeling.
-
CLINICAL_TRIALS trial_result · 2018-11-30Clinical Trial Update: Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management [Phase 4]
Phase 4 trial comparing ticagrelor with clopidogrel in Asian/Korean patients with acute coronary syndromes undergoing invasive management; c…
-
CLINICAL_TRIALS trial_result · 2018-11-30Clinical Trial Update: Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization [Phase 3]
Phase 3 clinical trial update examining vitamin E and N-acetylcysteine for preventing contrast-induced acute kidney injury after coronary ar…
-
FDA approval · 2018-11-23FDA Approved: EPTIFIBATIDE — Original Application (Baxter Healthcare Company)
FDA approval of Baxter Healthcare's original ANDA for eptifibatide (EPTIFIBATIDE), a generic injectable antiplatelet agent.
-
CLINICAL_TRIALS trial_result · 2018-11-07Clinical Trial Update: Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention [NA]
Completed clinical trial assessing genotype-guided dosing of antiplatelet therapy in patients undergoing percutaneous coronary intervention.
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: AngioSeal Versus Radial Approach in Acute Coronary Syndrome [Phase 4]
Phase 4 trial comparing AngioSeal vs radial approach in acute coronary syndrome has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2018-10-05Clinical Trial Update: A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk [Phase 2, Phase 3]
A pharmacodynamic study comparing a personalized P2Y12 inhibition strategy against ticagrelor to reduce ischemic and bleeding risk in acute …